These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27517679)

  • 1. Clinical Effects and Safety of Direct-Acting Insulin Analogs in Patients with Type 1 Diabetes: A Nation-Wide Observational Cohort Study.
    Lak V; Svensson AM; Miftaraj M; Franzén S; Eliasson B
    Diabetes Ther; 2016 Sep; 7(3):561-73. PubMed ID: 27517679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study.
    Svensson AM; Miftaraj M; Franzén S; Eliasson B
    Clin Diabetes Endocrinol; 2017; 3():5. PubMed ID: 28702259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes.
    Bramlage P; Tittel SR; Müther S; Reinhart-Steininger B; Haberland H; Khodaverdi S; Zimny S; Ohlenschläger U; Lanzinger S; Haak T
    Acta Diabetol; 2022 Nov; 59(11):1453-1460. PubMed ID: 35933650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine.
    Bode BW
    Endocr Pract; 2011; 17(2):271-80. PubMed ID: 21134878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
    Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
    Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application.
    Helms KL; Kelley KW
    Ann Pharmacother; 2009 Apr; 43(4):658-68. PubMed ID: 19336657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis.
    Nørgaard K; Sukumar N; Rafnsson SB; Saravanan P
    Diabetes Ther; 2018 Jun; 9(3):891-917. PubMed ID: 29623593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 20 Years of insulin lispro in pediatric type 1 diabetes: a review of available evidence.
    Kaiserman K; Jung H; Benabbad I; Karges B; Polak M; Rosilio M
    Pediatr Diabetes; 2017 Mar; 18(2):81-94. PubMed ID: 27390032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of insulin glulisine in patients with type 1 diabetes.
    Dreyer M; Prager R; Robinson A; Busch K; Ellis G; Souhami E; Van Leendert R
    Horm Metab Res; 2005 Nov; 37(11):702-7. PubMed ID: 16308840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing hyperglycemia from hospital admission to discharge.
    Moghissi ES
    Curr Med Res Opin; 2010 Mar; 26(3):589-98. PubMed ID: 20078323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.
    Nicolucci A; Ceriello A; Di Bartolo P; Corcos A; Orsini Federici M
    Diabetes Ther; 2020 Mar; 11(3):573-584. PubMed ID: 31873857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
    Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
    J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs.
    Lindström T; Hedman CA; Arnqvist HJ
    Diabetes Care; 2002 Jun; 25(6):1049-54. PubMed ID: 12032113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus.
    Morello CM
    Int J Gen Med; 2011; 4():827-35. PubMed ID: 22267935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
    Luzio S; Peter R; Dunseath GJ; Mustafa L; Owens DR
    Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety results from OCAPI: a European Observational Cohort Study of insulin glulisine-treated children aged 6-12 years with type 1 diabetes.
    Konstantinova M; Loizeau V; Pilorget V; Cali A; Danne T
    Exp Clin Endocrinol Diabetes; 2014 Oct; 122(9):523-7. PubMed ID: 25054310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study.
    Horvath K; Bock G; Regittnig W; Bodenlenz M; Wutte A; Plank J; Magnes C; Sinner F; Fürst-Recktenwald S; Theobald K; Pieber TR
    Diabetes Obes Metab; 2008 Jun; 10(6):484-91. PubMed ID: 17764465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.